Released · Last reviewed
Medicare's GLP-1 rules just changed twice. Here is the map.
For twenty years Medicare was barred from covering weight-loss drugs. In the space of eight months, a copay pilot and a negotiated price cut redrew that landscape.
Two separate programs now shape Medicare GLP-1 access. Yes, for some people: the Medicare GLP-1 Bridge lets eligible Part D and Medicare Advantage drug-plan enrollees get Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copay between July 1, 2026 and December 31, 2027, if they meet its BMI criteria. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1 instead. The $50 copay does not count toward the Part D out-of-pocket limit. Open Enrollment runs October 15 to December 7, 2026. Separately, Medicare's second round of drug-price negotiation set semaglutide (Ozempic, Wegovy, Rybelsus) at $274 per month effective January 1, 2027, a 71% cut from list price, with $385.63 listed for the Wegovy 2.4 mg package.
The GLP-1 Bridge pilot: what it is
The Bridge program is a short-term CMS demonstration that provides eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management at a flat copay of $50 per month, beginning July 1, 2026. It grew out of the November 2025 agreements between the administration and both manufacturers — Novo Nordisk and Eli Lilly — that traded lower government prices for expanded access channels.
It is a pilot, not a permanent benefit. It covers Foundayo, Wegovy and the Zepbound KwikPen only, for enrollees who meet its BMI criteria; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible, though their Part D plan might cover a GLP-1. CMS extended it through December 31, 2027. The historical significance is hard to overstate: Part D has excluded drugs used for weight loss since the program's creation in 2006, and the Bridge is the first Medicare route for obesity treatment at scale, and it runs outside the Part D benefit.
| Program / price | Amount | Effective | Applies to |
|---|---|---|---|
| GLP-1 Bridge pilot copay | $50/mo | Jul 1, 2026 | Eligible Part D members, weight management |
| Negotiated semaglutide (MFP) | $274/mo | Jan 1, 2027 | Ozempic, Wegovy, Rybelsus via Part D |
| Negotiated Wegovy 2.4 mg package | $385.63 | Jan 1, 2027 | Per CMS documents |
| Part D OOP cap | $2,100 (2026); $2,400 (2027) | Active | All Part D members |
The 2027 negotiated price: $274 for semaglutide
On November 25, 2025, CMS announced negotiated prices for the second cycle of the Medicare Drug Price Negotiation Program, effective January 1, 2027. Semaglutide headlines the list: Ozempic, Wegovy and Rybelsus were negotiated as one active ingredient, landing at $274 per 30-day supply against a list price near $959 — a 71 percent reduction. CMS's fact sheet lists $385.63 for the Wegovy 2.4 mg package (four pens).
Tirzepatide (Mounjaro/Zepbound) was not in this cycle; analysts expect it in a later round, with any negotiated price taking effect in 2028 or 2029.
The confusing part: three different prices at once
Between now and 2027, three price regimes overlap. The negotiated Medicare maximum fair price is $274 from January 2027; and self-pay programs (such as NovoCare and LillyDirect) list $149 to $699 depending on drug and dose. These are different prices for different buyers, and none of them is automatically what a beneficiary pays at the counter.
What a beneficiary pays depends on their Part D plan's formulary tier, deductible phase and coinsurance — the negotiated price caps what Medicare pays the manufacturer, and out-of-pocket costs flow from plan design. The Part D out-of-pocket cap ($2,100 in 2026, $2,400 in 2027) remains the beneficiary's backstop.
Indication still decides everything
Traditional Part D coverage of GLP-1s still runs through non-weight-loss indications: type 2 diabetes (Ozempic, Mounjaro, Rybelsus), established cardiovascular disease risk reduction (Wegovy's SELECT-based indication), and obstructive sleep apnea (Zepbound). If you qualify under one of those, standard Part D coverage plus the 2027 negotiated price is your path, and the Bridge pilot is irrelevant to you.
If your only indication is weight management, the Bridge is currently the only Medicare route, and its eligibility rules govern. This split will keep producing situations where two people on the identical drug pay very different amounts — the deciding variable is the diagnosis code, not the medication.
What to do, by situation
If you have diabetes, CVD or diagnosed OSA: confirm your 2026 plan's formulary tier for your specific drug now, and expect the semaglutide line to reprice in January 2027 — plans will update tiers during the fall 2026 open enrollment, which is the moment to compare.
If you want GLP-1 treatment for weight alone: check the Bridge's BMI criteria with your prescriber; the Bridge runs outside your plan's Part D benefit and CMS says plan sponsors do not need to opt in. If you are not eligible, your realistic 2026 options are manufacturer self-pay channels ($149 to $699 by drug and dose) or compounded programs ($49 to $279 a month for semaglutide in our October 15, 2026 read), with the compounded route carrying its usual non-FDA-approved caveats. Manufacturer copay cards, note, cannot legally be combined with Medicare.
One more moving part deserves attention: the interaction between Medicare's changes and the compounded market. Compounded GLP-1s cannot be billed to Medicare and manufacturer copay cards cannot be combined with it, so for beneficiaries the real 2026–2027 comparison is Bridge-pilot copay versus negotiated Part D price versus cash-pay self-funding. As the negotiated $274 price and the pilot mature, the cash-pay compounded route loses much of the price advantage that drove Medicare-age patients toward it, while carrying regulatory and quality risk that insured brand access does not. For most eligible beneficiaries, the durable answer will be a covered indication plus the 2027 price, with the Bridge pilot bridging exactly the gap its name implies.
Frequently asked questions
Does Medicare now cover Wegovy for weight loss?
Only through the GLP-1 Bridge demonstration beginning July 1, 2026, for eligible beneficiaries in Part D or Medicare Advantage drug plans (plans do not need to opt in). Standard Part D coverage still requires a non-weight-loss indication like CVD risk reduction.
Will I pay $274 at the pharmacy in 2027?
Not necessarily. $274 is the negotiated maximum fair price Medicare pays; your cost depends on your plan's tier and coinsurance. It should fall substantially, but check your plan's 2027 documents in the fall 2026 open enrollment.
Is tirzepatide getting a negotiated price too?
Not in this cycle. Mounjaro and Zepbound are widely expected in a subsequent negotiation round, with prices effective 2028 or 2029. Zepbound access in 2026 runs through the Bridge pilot, the OSA indication, or self-pay.
Sources
- CMS negotiated prices via NPR, Nov 26, 2025
- BioPharma Dive on the 2027 price list
- GLP-1 Bridge details via Managed Healthcare Executive
- CMS Medicare Drug Price Negotiation Program
The numbers behind this page
How this guide is kept current
Every price quoted in this guide comes from the programme's own pricing page and carries the date it was captured. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
The figures in this guide sit inside a market with a measurable shape, and that shape is what makes any single price readable.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.